NOXXON to Participate in Biotech and Health-Tech Conferences in October 2021 – Yahoo Finance

NOXXON to Participate in Biotech and Health-Tech Conferences in October 2021 – Yahoo Finance

BERLIN, September 29, 2021–(BUSINESS WIRE)–Regulatory News:

NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announces that Aram Mangasarian, CEO of NOXXON, will participate in HealthTech Innovation Days and the Biotech in Europe Forum in early October.

HealthTech Innovation Days, October 4-5, Paris
HealthTech Innovation Days, organized by France Biotech, aims to bring together European healthcare stakeholders and promote the transformation of an integrated ecosystem. Mr. Mangasarian will be available for in-person investor meetings at the conference. More information about the event can be found here.

Annual Biotech in Europe Forum, October 7-8, digital conference
Mr. Mangasarian will participate in a panel discussion at the event organized by the Sachs Associates. The session entitled “Immuno-Oncology BD&L Panel” is scheduled on Friday, October 8, 2021 at 11:20 a.m. CEST and will be chaired by speakers from Locust Walk and Merck. Aram Mangasarian will share the floor with Corinne Venot from BeiGene, Khatereh Ahmadi from MSD and Phil L’Huillier from CatalYm. To request a one-on-one meeting with NOXXON please contact us via the conference platform or at [email protected] More information about the event can be found here.


NOXXON’s oncology-focused pipeline acts on the tumor microenvironment (TME) and the cancer immunity cycle by breaking the tumor protection barrier and blocking tumor repair. By neutralizing chemokines in the TME, NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. NOXXON’s lead program NOX-A12 has delivered final top-line data from a Keytruda® combination trial in metastatic colorectal and pancreatic cancer patients published at the ESMO conference in September 2020 and in July 2021 the company announced its Phase 2 study, OPTIMUS, to further evaluate safety and efficacy of NOX-A12 in combination with Merck’s Keytruda® and two different chemotherapy regimens as second-line therapy in patients with metastatic pancreatic cancer. NOXXON is also studying NOX-A12 in brain cancer in combination with radiotherapy which has been granted orphan drug status in the US and EU for the treatment of certain brain cancers. GLORIA, a trial of NOX-A12 in combination with radiotherapy in newly diagnosed brain cancer patients who will not benefit clinically from standard chemotherapy has delivered interim data from the first two cohorts showing consistent tumor reductions and objective tumor responses. The company’s second clinical-stage asset NOX-E36 is a Phase 2 TME asset targeting the innate immune system. NOXXON plans to test NOX-E36 in patients with solid tumors. Further information can be found at:

Keytruda® is a registered trademark of Merck Sharp & Dohme Corp

Visit NOXXON on LinkedIn and Twitter

About the GLORIA Study

GLORIA (NCT04121455) is NOXXON’s dose-escalation, phase 1/2 study of NOX-A12 in combination with irradiation in first-line glioblastoma (brain cancer) patients with unmethylated MGMT promoter (resistant to standard chemotherapy).

About the OPTIMUS Study

OPTIMUS (NCT04901741) is NOXXON’s open-label two-arm phase 2 study of NOX-A12 combined with pembrolizumab and nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nab-paclitaxel in microsatellite-stable metastatic pancreatic cancer patients.


Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial indicators, developments of the financial situation or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for updating such information, which only represents the state of affairs on the day of publication.

View source version on


NOXXON Pharma N.V.
Aram Mangasarian, Ph.D.
Chief Executive Officer
Tel. +49 (0) 30 726247 0
[email protected]

Investor and Media Relations:

LifeSci Advisors
Guillaume van Renterghem
Tel. +41 (0) 76 735 01 31
[email protected]

Arthur Rouillé
Tel. +33 (0) 1 44 71 00 15
[email protected]